Chongqing Pharscin Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chongqing Huasen Pharmaceutical Co., Ltd. (stock abbreviation: Huasen Pharmaceutical, stock code: 002907) is a national key high-tech enterprise that integrates drug research and development, production, and sales, and an A-share listed company on the Shenzhen Stock Exchange. Over the years, the company has successively won the National Enterprise Technology Center, National Technology Innovation Demonstration Enterprise, National Advanced Private Enterprise in Employment and Social Security, Health China Quality Award, China Patent Award, National Worker Pioneer, Top 100 Chinese Non prescription Drug Enterprises, 70 Week Old Pharmaceutical Industry Benchmark Enterprise of the People's Republic of China, National Contract abiding and Credit Valuing Enterprise, National Intellectual Property Demonstration Enterprise, and Top 100 Chinese Traditional Chinese Medicine Enterprise Rankings Chongqing Advanced Grassroots Party Organization, China Industrial Internet Outstanding Application Award, Top 100 Manufacturing Enterprises in Chongqing, Top 50 Enterprises in Chongqing Private Enterprise Science and Technology Innovation Index, and other honors. For three consecutive years, it has received an "A" level evaluation in the Shenzhen Stock Exchange's credit rating assessment, and has established a postdoctoral research workstation and a Chongqing Haizhi workstation. Huasen Pharmaceuticals has Beijing Huasen Inno Biotechnology Co., Ltd. and Beijing Bosen Biotechnology Co., Ltd. PharscinUSA Inc (Huasen Pharmaceutical (USA) Co., Ltd.), Chongqing Huasen Biotechnology Co., Ltd., Chongqing Huasen Pharmaceutical Co., Ltd., and Chongqing Huasen Pharmacy Retail Chain Co., Ltd. In line with the concept of "science and technology leading, innovation driving, inheritance of essence, integrity and innovation", Huasen Pharmaceutical has created high-quality products that are "specialized, refined, special and new". At present, the company has 75 drug approval numbers, including traditional Chinese patent medicines and simple preparations, chemical raw materials and preparations, including 53 drugs listed in the national "medical insurance" catalogue, 49 national drug standards, 72 patents, and has undertaken 120 scientific and technological research and development projects of national, provincial and municipal ministries. In terms of innovative drug research and development, Watson Pharmaceutical has promoted the implementation of innovative drug research and development strategy, focused on the development of the first in class and best in class drugs in the same category, promoted the differentiated research and development pipeline, and committed to building an innovative drug research and development team with an international perspective. At present, the company has four self-developed tumor 1.1 innovative drug research projects, with potential indications covering tumor immunity, lung cancer, breast cancer, colorectal cancer Pancreatic cancer and other solid tumors; We have established three innovative drug technology platforms based on functional genomics, including a screening platform for biological activity of different types of targeted molecules, a testing platform for drug metabolism and pharmacokinetics, and a platform for structural design and synthesis of small molecule drugs targeting specific targets. We have the ability to develop innovative drugs from drug discovery to preclinical development, achieving breakthroughs in innovative drugs from 0 to 1. In terms of external cooperation of innovative drugs, Chengdu Aorui Pharmaceutical Co., Ltd., a new drug research and development company based on artificial intelligence drug discovery technology platform dedicated to small molecule targeted innovative drugs, was established through cooperation with the scientific research achievements transformation platform of the State Key Laboratory of Biotherapy of Sichuan University; Collaborate with China Academy of Computing Technology Western Research Institute and Beijing Zheyuan Technology Co., Ltd. to carry out screening of new tumor drug targets, candidate drug development, translational medicine research, preclinical and clinical development, registration application, market access, and other work, creating new heights of biopharmaceutical innovation. In the research and development of generic drugs, traditional Chinese patent medicines and simple preparations and special medical food, the company has implemented the research and development strategy of "excellent production cost, rapid research and development, and high technical barriers", and has laid out digestive system, mental nervous system, respiratory system, tumor, postoperative weight loss and other fields, Through continuous accumulation of project experience, technical platforms such as the "API Engineering Conversion Research Platform, Industrial Pharmacy Prescription Design and Process Amplification Research Platform, and CMC (Chemistry and Quality Control) and Impurity Quantitative Analysis Research Platform" have been established. In terms of establishing a common R&D platform, the company has established a testing center, which has passed CNAS certification (the first pharmaceutical enterprise in Chongqing to pass CNAS certification). Huasen Pharmaceutical has built a "5G+Industrial Internet" smart factory in the Rongchang National High tech Zone, with 22 production lines for tablets, soft capsules, freeze-dried powder injections, raw material drug synthesis, and traditional Chinese medicine pretreatment and extraction. It is also the first production line for special medical purpose formula food in the southwest region. We have established a fully automated intelligent traditional Chinese medicine extraction production line and a modern warehousing and logistics center, fully implementing artificial intelligence systems such as MES, BMS, EMS, SCADA, DCS, and passing the on-site inspection and certification of FDA's cGMP with zero "483" defects. We plan to create an international drug CDMO production platform.We have been awarded the titles of National Intelligent Manufacturing Demonstration Factory, First Batch of Classified and Classified Security Management Innovation Application Demonstration Enterprise by the Ministry of Industry and Information Technology, Excellent Pilot Enterprise for Classified and Classified Management of Industrial Internet Network Security by the Ministry of Industry and Information Technology, Top Ten 5G+Industrial Internet Pilot Demonstration Enterprises in Chongqing, and Outstanding Application Award of China Industrial Internet in 2021. Huasen Pharmaceutical always adheres to the promotion of professional chemical techniques, conveying leading, accurate, and up-to-date information and services to medical workers. At present, the academic network has covered 31 provinces, cities, and autonomous regions across the country. Huasen Pharmaceutical actively fulfills its social responsibility and adopts the "company+research institute+farmers" model to establish standardized planting bases for traditional Chinese medicine in Rongchang, Xiushan, Wanzhou and other places in Chongqing, participating in targeted poverty alleviation and driving local farmers to increase income and become rich; The company has donated over 5 million yuan in drugs and medical protective materials to the frontline of epidemic prevention in Wuhan, Chongqing, and other areas; The 512 Wenchuan earthquake relief and the 4.20 Ya'an earthquake... every public welfare site is filled with the presence of Huasen people. It has successively won the honors of "Caring Unit", advanced private enterprise in Chongqing's fight against COVID-19, advanced private enterprise in the targeted poverty alleviation action of "10000 enterprises helping 10000 villages", and top ten demonstration pharmaceutical enterprises with outstanding contributions in Chongqing. Huasen Pharmaceuticals regards talent as the primary resource for enterprise development, always adhering to the talent strategy of "people-oriented and employee achievement", providing comprehensive training for employees, and introducing multiple welfare insurance systems to provide sustainable development space for employees. At the same time, the company focuses on creating a corporate culture atmosphere of "Huasen is my home", improving employees' sense of belonging and initiative, and achieving employee happiness. We have successively won honors such as Chongqing Civilized Unit, National Model Workers' Home, Chongqing March 8th Red Flag Collective, May 1st Labor Award, and have been awarded the Outstanding Employer of the Year in Chongqing multiple times. Huasen Pharmaceutical takes "developing good drugs, healthy humans, and achieving employees" as its corporate mission, adhering to the values of "integrity, diligence, gratitude, learning, teamwork, and innovation", and striving continuously for the Huasen Dream of "making good Chinese medicine and going global" with solid steps. It contributes to the construction of the Chengdu Chongqing dual city economic circle and the realization of the Chinese Dream of the great rejuvenation of the Chinese nation. |
| Headquarter | Chongqing |
| Establish Date | 11/4/1996 |
| Listed Code | 002907.SZ |
| Listed Date | 10/20/2017 |
| Chairman | You Hongtao. |
| CEO | Liu Xiaoying. |
| Website | www.pharscin.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
